Revenue - Accounts Receivable, Unbilled Services, and Deferred Revenue (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jul. 31, 2022
Accounts receivable:
Accounts receivable, beginning balance		$ 454,993,000	$ 262,012,000
Additions		1,768,457,000	2,432,268,000
Deductions		(2,127,240,000)	(2,239,287,000)
Accounts receivable, ending balance	$ 96,210,000	96,210,000	454,993,000	$ 262,012,000
Allowance for doubtful accounts:
Allowance for doubtful accounts, beginning balance		0	0
Additions		(13,835,000)	0	0
Deductions		0	0
Allowance for doubtful accounts, end balance	(13,835,000)	(13,835,000)	0	0
Deferred revenue
Deferred revenue, beginning balance		1,595,472,000	273,228,000
Additions		46,908,000	1,598,152,000
Deductions		(1,092,829,000)	(275,908,000)
Deferred revenue, ending balance	549,551,000	549,551,000	1,595,472,000	273,228,000
Disaggregation of Revenue [Line Items]
Bad debt expense		13,835,000	0	0
Deferred revenue, current	370,137,000	370,137,000	1,422,944,000	300,000,000
Deferred revenue, noncurrent	179,414,000	179,414,000	172,528,000	0
Deferred revenue	549,551,000	549,551,000	$ 1,595,472,000	$ 273,228,000
Collaboration agreement upfront payment amount	819,000,000	819,000,000
Revenue, performance obligation satisfied at previous quarter	41,900,000
Revenue
Deferred revenue
Deferred revenue, ending balance	273,800,000	273,800,000
Disaggregation of Revenue [Line Items]
Deferred revenue	273,800,000	273,800,000
Gavi Advance Purchase Agreement- COVAX Facility
Disaggregation of Revenue [Line Items]
Collaboration agreement upfront payment amount	697,400,000	697,400,000
Joint Committee on Vaccination and Immunization (JCVI)
Deferred revenue
Deferred revenue, ending balance	112,500,000	112,500,000
Disaggregation of Revenue [Line Items]
Deferred revenue	112,500,000	112,500,000
Collaboration agreement upfront payment amount	$ 112,500,000	$ 112,500,000			$ 225,000,000